PDF
ZENODO
CERTIFICATE
Published
2024-02-14
Section
Articles
How to Cite
How to Cite
VIROCIDAL ACTIVITY OF EGYPTIAN SCORPION VENOMS AGAINST HEPATITIS C VIRUS
Xojimurodov Davronjon Ikramaliyevich
Angren University, Angren City, Tashkent Region Teacher of the Faculty of Medicine Angren University, Angren City,
Mirzayev Furqat Farhod o'g'li
Tashkent Region Teacher of the Faculty of Medicine
Keywords: Keywords: Hepatitis C virus, HCV, Antiviral activity, Scorpion venom, Scorpio maurus palmatus, Egypt, HCV-Hepatitis C virus, SVR-Sustained virological response, AMPs-Antimicrobial peptides, CC50-50% cytotoxic concentration,IC50 -50% inhibitory concentration.
Abstract
Hepatitis C virus (HCV) is a major global health problem, causing chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. Development of well-tolerated regimens with high cure rates and fewer side effects is still much needed. Recently, natural antimicrobial peptides (AMPs) are attracting more attention as biological compounds and can be a good template to develop therapeutic agents, including antiviral agents against a variety of viruses. Various AMPs have been characterized from the venom of different venomous animals including scorpions.
References
Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Micro.
Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature.
Calland N, Dubuisson J, Rouillé Y, Séron K. Hepatitis C virus and natural compounds: a new antiviral approach? Viruses.
Gentile I, Borgia F, Coppola N, Buonomo AR, Castaldo G, Borgia G. Daclatasvir: the first of a new class of drugs targeted against hepatitis C virus NS5A. Curr Med Chem.
Suzuki F, Toyota J, Ikeda K, Chayama K, Mochida S, Hayashi N, et al. A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection. Antivir.
Poordad F, Lawitz E, Kowdley KV, Cohen DE, Podsadecki T, Siggelkow S, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med.
Lok AS, Gardiner DF, Hèzode C, Lawitz EJ, Bourlière M, Everson GT, et al. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatol.
